Acumen Pharmaceuticals, Inc.
ABOS
$2.72
$0.041.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -284.65% | -19.37% | 90.06% | 102.96% | 160.05% |
| Gross Profit | 284.65% | 19.37% | -90.06% | -102.96% | -160.05% |
| SG&A Expenses | -7.06% | -9.43% | -4.60% | -4.15% | -3.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.36% | -17.83% | 71.24% | 70.87% | 114.20% |
| Operating Income | 36.36% | 17.83% | -71.24% | -70.87% | -114.20% |
| Income Before Tax | 32.34% | 11.13% | -99.40% | -93.61% | -125.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.34% | 11.13% | -99.40% | -93.61% | -125.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.34% | 11.13% | -99.40% | -93.61% | -125.22% |
| EBIT | 36.36% | 17.83% | -71.24% | -70.87% | -114.20% |
| EBITDA | 36.37% | 17.83% | -71.29% | -70.94% | -114.34% |
| EPS Basic | 32.89% | 11.85% | -97.78% | -91.31% | -117.44% |
| Normalized Basic EPS | 32.88% | 11.85% | -97.80% | -91.38% | -117.50% |
| EPS Diluted | 32.89% | 11.85% | -97.78% | -91.31% | -117.44% |
| Normalized Diluted EPS | 32.88% | 11.85% | -97.80% | -91.38% | -117.50% |
| Average Basic Shares Outstanding | 0.82% | 0.82% | 0.82% | 1.19% | 3.56% |
| Average Diluted Shares Outstanding | 0.82% | 0.82% | 0.82% | 1.19% | 3.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |